Join our daily newsletter At The Bell to receive exclusive market insights
- Chimeric Therapeutics (ASX:CHM) treats the first patient in its Advent-AML phase 1B clinical trial at The University of Texas MD Anderson Cancer Center.
- It’s the first clinical trial to evaluate NK cell therapy in combination with the current standard of care for Acute Myeloid Leukemia patients
- CHM 0201 cells recently underwent manufacturing and release testing before commencing the trial
- The lead Principal Investigator intends to enrol 20 patients with newly diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell transplant
- CHM shares are up eight per cent, trading at 2.7 cents at 1:19 pm AEDT
Chimeric Therapeutics (ASX:CHM) has treated the first patient in its Advent-AML phase 1B clinical trial at The University of Texas MD Anderson Cancer Center.
It’s the first clinical trial evaluating NK cell therapy in combination with the current standard of care for Acute Myeloid Leukemia (AML) patients, which is Azacitidine and Venetoclax.
CHM 0201 represents a potentially leading-edge, clinically validated NK cell platform.
Results from the phase 1A clinical trial were released in March 2022, showcasing both safety and efficacy across blood cancers and solid tumours.
Leveraging the CHM 0201 platform, Chimeric has launched the development of innovative next-generation NK and CAR NK assets.
“We are very happy to report this progress in the ADVENT-AML clinical trial,” CHM Chief Medical Officer and Managing Director Jason B Litten said.
“The novel combination of CHM 0201 with the standard of care in AML treatment has the potential to transform frontline therapy and enhance outcomes for AML patients.”
CHM 0201 cells recently underwent manufacturing and release testing before commencing the trial.
Lead Principal Investigator, Abhishek Maiti MD, Assistant Professor in the Department of Leukemia intends to enrol up to 20 patients with newly diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell transplant.
CHM shares were up eight per cent, trading at 2.7 cents at 1:19 pm AEDT.
